Poster presentations to take place on Wednesday September 16th in Philadelphia, Pennsylvania
First Published: 11 September, 2026
Cumulus Neuroscience will present data at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, taking place 16–17 September 2026 at The Westin Philadelphia. Three posters will be presented, spanning neuropsychiatry and neurodegeneration. Two report interim data from studies conducted in collaboration with a leading pharmaceutical company and academic partners; the third is an encore presentation of work first shown at the Alzheimer’s Association International Conference (AAIC) 2026 in London on 15 July.
“The NeuLogiq® Platform was purpose-built in collaboration with 10 top biopharma companies to generate objective, clinical-quality data in CNS clinical trials, with an initial focus in Alzheimer’s dementia,” said Brian Murphy, PhD, Co-Founder and Chief Scientific Officer of Cumulus. “The posters we’re presenting at ISCTM this year extend that work across neuropsychiatry — remote, multimodal monitoring in borderline personality disorder and in treatment-resistant depression — alongside an encore of our Alzheimer’s pre-enrichment data. In each case the question is the same: can we collect richer data more frequently, while asking less of patients and sites?”
The posters were accepted by the ISCTM Scientific Program Committee for presentation at the meeting. Live poster presentation will take place on Wednesday 16 September 2026, 5:50–7:30 PM EDT:
Poster 1:
Poster 2:
Poster 3, encore presentation — in collaboration with the University of Bath and the University of Bristol
Cumulus supports precision in CNS clinical trials for its industry partners by enabling in-clinic and remote monitoring of patients across multiple domains of brain function.
FOR MORE INFORMATION
Tina Sampath
Tina.Sampath@cumulusneuro.com